ICIs targeting PD-1/PD-L1, CTLA-4, lymphocyte activating gene 3 (LAG3), and CD47/SIRP- have been approved by the FDA for use in a range of solid tumors and hematological malignancies. Here, LAG3 is linked to hematologic disorder.